VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZNTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZNTLZentalis Pharmaceuticals, Inc.
$1.36$97M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ZNTL
  4. Financial Ratios

Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Ratios

Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -49.5%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ZNTL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$97M$97M$215M$991M$1.1B$3.6B$2.1B——
Enterprise Value$100M$101M$224M$1.0B$1.1B$3.6B$2.1B——
P/E Ratio →-0.81————————
P/S Ratio——3.19——————
P/B Ratio0.450.450.642.272.459.856.39——
P/FCF—————————
P/OCF—————————

P/E links to full P/E history page with 30-year chart

ZNTL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue——3.32——————
EV / EBITDA—————————
EV / EBIT—————————
EV / FCF—————————

ZNTL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin——100.0%—————100.0%
Operating Margin——-283.6%—————-169878.6%
Net Profit Margin——-246.0%—————-150478.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-49.5%-49.5%-42.8%-67.1%-59.3%-45.5%-58.7%-90.7%-65.2%
ROA-38.1%-38.1%-33.4%-52.4%-46.2%-37.9%-51.9%-70.7%-51.4%
ROIC-40.5%-40.5%-35.8%-50.3%-43.2%-51.5%-62.7%-650.4%-249.4%
ROCE-48.5%-48.5%-43.9%-60.5%-49.1%-56.6%-57.9%-86.6%-68.4%

ZNTL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.180.180.130.100.110.130.010.04—
Debt / EBITDA—————————
Net Debt / Equity—0.020.030.040.01-0.04-0.16-0.95-0.78
Net Debt / EBITDA—————————
Debt / FCF—————————
Interest Coverage————-91.26————

ZNTL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio6.936.937.327.167.987.9812.074.624.30
Quick Ratio6.936.937.327.167.987.9812.074.624.30
Cash Ratio6.736.737.046.967.727.7411.844.514.05
Asset Turnover——0.16—————0.00
Inventory Turnover—————————
Days Sales Outstanding——27.07—————23907.50

ZNTL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield—————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$72M$71M$65M$53M$43M$41M$36M$18M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Shrinking cash cushion against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Discount to Book Reflects Impaired Earnings Power

ZNTL trades at a P/B of 0.57 while carrying negative trailing earnings with a P/E of -0.90, so the market is pricing the balance sheet at a steep discount to its stated book value according to reported figures.

A sub-1.0 price-to-book multiple paired with negative earnings indicates the market doubts that book equity will be converted into future cash returns, which is consistent with the reported equity erosion from an accumulated deficit near -$1.3B. Because forward multiples and EV-based metrics are unavailable, valuation cannot be benchmarked against own history or the sector, and peers such as RVMD and PRAX trade at much higher book multiples, which may simply reflect differing pipeline expectations rather than a clear mispricing. Investors should monitor whether the discount narrows as cash burn is funded, since further dilution could compress book value per share further.

Operating Losses Overwhelm Thin Revenue Base

Operating margin deteriorated to roughly -185.6% in 2024Q4 and net margin reached -176.7%, with ROE at -47.6% in 2026Q2, indicating losses far exceed any reported revenue, based on reported figures.

Margin data is sparse after 2024Q4, so the trajectory cannot be fully tracked, but the available readings show expenses running at multiples of revenue rather than a modest gap that scale could close. Relative to the peer group, ZNTL's negative ROE sits in line with clinical-stage peers such as IMVT and PRAX rather than the profitable AUPH and TGTX, suggesting the gap is structural to the pre-commercial model rather than temporary. The more informative measure of earning power for this company is the cash burn rate, since non-cash stock compensation has inflated the reported operating cost base.

Negative Returns Deepen as Capital Base Shrinks

ROIC fell from -4.0% in 2024Q1 to -36.1% in 2026Q2 while ROE moved to -47.6%, reflecting a sustained decay in returns on invested capital, according to the reported quarterly ratios.

The decline in ROIC is driven primarily by a shrinking invested capital base combined with widening losses, rather than by any improvement in capital efficiency, which means returns are being eroded from both the numerator and denominator. Compared with the peer set, ZNTL's ROIC sits well below AUPH and TGTX, which both generate positive returns, and roughly in line with PRAX and KYMR, which are also loss-making. The trend implies the company is currently decaying rather than compounding capital, and investors should monitor whether ROIC stabilizes as burn is reduced.

Elevated Current Ratio Conceals Shrinking Cash Buffer

The current ratio of 4.82 in 2026Q2 appears comfortable, yet cash declined from $41.9M in 2025Q1 to $24.8M, which suggests the liquidity cushion is thinning faster than the ratio implies, based on reported figures.

A current ratio near 5 looks strong in isolation, but it is supported largely by short-term assets that are being consumed by operating burn, so the ratio is declining from its prior 9.19 reading in 2024Q1. Under a severe stress scenario with continued quarterly losses near the reported -$77.6M net loss, the existing cash balance would cover only a fraction of a year of operations, which would warrant further investigation of financing plans. Because the quick ratio matches the current ratio, the company holds essentially no inventory, so liquidity depends entirely on cash and receivables rather than working capital turnover.

Low Leverage Understates Funding Dependence

A debt-to-equity ratio of 0.23 looks conservative, but it likely understates risk because equity is shrinking while the company burns cash, based on reported figures.

The apparent safety of low leverage is largely a function of the shrinking equity denominator, since total debt has stayed near $34M to $45M while equity has fallen, so the D/E increase from 0.10 to 0.23 reflects erosion of the cushion rather than new borrowing. The most commonly misapplied ratio for a clinical-stage biotech is the current ratio, which can appear strong even when the cash runway is short. A more appropriate lens is months of cash runway measured against the quarterly burn rate, which the reported figures suggest is considerably shorter than the balance sheet ratios imply.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open ZNTL Terminal

ZNTL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ZNTL — Frequently Asked Questions

Quick answers to the most common questions about buying ZNTL stock.

What is Zentalis Pharmaceuticals, Inc.'s P/E ratio?

Zentalis Pharmaceuticals, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.

What is Zentalis Pharmaceuticals, Inc.'s ROE?

Zentalis Pharmaceuticals, Inc.'s return on equity (ROE) is -49.5%. The historical average is -59.8%.

Is ZNTL stock overvalued?

Based on historical data, Zentalis Pharmaceuticals, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.